Company profile
KRYSTAL BIOTECH, INC.
NASDAQ:KRYSBiotechnology: Biological Products (No Diagnostic Substances)
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| VYJUVEK | approved | $119.2MQ2 2026 | 0 | — |
| INETAGUGENE GEPERPAVEC | phase2 | — | 2 | unknown |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (15)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04917874 | phase3 | completed | 2021-05-25 | 2023-07-31 | Krystal Biotech, Inc. | A Long-term Treatment With B-VEC for Dystrophic Epidermolysis Bullosa |
| NCT04540900 | phase1 | active_not_recruiting | 2020-10-07 | 2024-10-16 | Krystal Biotech, Inc. | A Phase I Study of KB301, a Replication-Incompetent, Non-Integrating Vector Expressing Human Type III Collagen (COL3) for the Treatment of Superficial Skin Depressions |
| NCT03536143 | phase1_2 | completed | 2018-05-06 | 2019-11-01 | Krystal Biotech, Inc. | A Phase I/II Study of KB103, a Topical HSV1-COL7, on DEB Patients |
| NCT06724900 | phase1_2 | active_not_recruiting | 2024-11-20 | 2025-07-01 | Krystal Biotech, Inc. | A Study Assessing KB304 for the Treatment of Wrinkles in Women |
| NCT05504837 | phase1 | recruiting | 2023-06-30 | 2026-12-01 | Krystal Biotech, Inc. | A Study Assessing KB407 for the Treatment of Cystic Fibrosis |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| BLA 125774 | 2023-05-19 | BLA | KRYSTAL BIOTECH, INC. | |||||
Loading… | ||||||||